Exact Sciences is building a brand it hopes will become intimately linked with cancer testing. Once it does that, it will not need to spend as much on sales and marketing to attract customers.

Exact Sciences stock is seeing consistent revenue growth, but the upside looks limited. Learn why investors need to pay close ...

Exact Sciences is building a cup without handle with a 72.83 buy point.See if it can clear the breakout price in volume at least 40% above average. Exact Sciences reported 0% EPS growth in its ...

Exact Sciences Q3 Earnings: Profitability Goal Execution Momentum Building Into 2023. Nov. 09, 2022 10:45 PM ET Exact Sciences Corporation (EXAS) Stock EXAS 4 Comments 5 Likes. Bashar Issa.

Building on the success of the Cologuard and Oncotype DX tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

EXAS Price Action: Exact Sciences has a 52-week high of $84.46 and a 52-week low of $29.27. The stock was up 16.1% at $54.72 at time of publication, according to Benzinga Pro . Photo: courtesy of ...

MADISON, Wis., May 01, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million ...

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around ...

Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.